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Deep Mining for Determining 
Cancer Biomarkers
The use of omics data for knowledge discovery is an approach that can 
be used for personalised cancer medicine and for a better understanding 
of cancer genotype and phenotype. Three researchers have developed a 
deep feature learning model to discover biomarkers that are positively and 
negatively associated with cancer. HealthManagement.org spoke to Abeer 
Alzubaidi, Jonathan Tepper and Ahmad Lotfi to find out more about this 
new approach and its potential.
 Interviewee: Abeer Alzubaidi | School of Science and Technology | Nottingham Trent University | 
Nottingham, UK
 Interviewee: Jonathan Tepper | CEO | Percepetronix Ltd. | UK
 Interviewee: Ahmad Lotfi | Professor of Computational Intelligence | Nottingham Trent University 
| Nottingham, UK | Visiting Professor | Tokyo Metropolitan University
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What do you think are the most significant limitations in 
harnessing omics data in the biomedical space?  
Extracting knowledge from omics datasets is a serious chal-
lenge for the research community interested in understanding 
the cancer genotype and phenotype. Such datasets are char-
acterised by high dimensionality and relatively small sample 
sizes with small signal-to-noise ratios. This significantly chal-
lenges existing machine learning-based solutions due to 
the so-called ‘curse of dimensionality’ where the addition of 
new input features typically requires an exponential number 
of input observations (which are commonly unavailable) to 
discover the underlying structure of the data that allows these 
models to generalise well to unseen cases. This also puts great 
pressure on data mining models that attempt to separate the 
signal from the noise in a bid to discover robust determinants.
Describe how the non-linear sparse auto-encoders in 
your deep learning model work? 
The Sparse Compressed Auto-Encoder (SCAE) is simply a 
feedforward neural network trained with a variant of back-
propagation to reproduce its input signal on its output layer, 
resulting in a hidden or latent feature layer of neurons repre-
senting the underlying transformation performed. The principle 
idea behind our SCAE model is to transform the original high 
dimensional omics data into a reduced feature space so that 
enough of the interesting complexity can be retained whilst 
not requiring additional observations to further constrain the 
model. This reduced description of the omics data is further 
realised through a regularisation technique within SCAE that 
maximises the likelihood of retaining important input signals 
describing much of the variance within the data, whilst filtering 
out the less important and noisy signals.  
The Stacked Sparse Compressed Auto-Encoder (SSCAE) is 
composed of a sequence of SCAE trained in a dependent and 
co-operative manner, where the hidden feature layer of one 
model feeds as input to another. The underlying complexity 
of omics data is compactly represented with multiple levels of 
abstraction, therefore, we apply a greedy recursive approach to 
transforming the input signals containing tens of thousands of 
genes into a hidden representation of a lower dimension and 
higher abstraction, which is then provided as input to another 
SCAE, which encodes this further at a higher abstract level and 
so on. The resulting abstract hidden layer is then provided as 
input to the final layer of SSCAE (i.e. the output layer), which is 
a softmax classification layer trained to classify the input as 
belonging to either a patient with or without cancer. 
In addition, we augmented a novel weight interpretation 
feature into SSCAE such that we were able to determine which 
original features on the input layer were most highly predic-
tive, positively and negatively associated with the positive 
patient groups e.g. cancer, ER+/PR+. This method is simply 
based on computing the integrated weight score for each 
gene within the original input data that indicates its contribu-
tion to the latent representations formed within SSCAE during 
learning. This expands our deep learning model to include a 
feature selection method in addition to the feature extrac-
tion capacity already inherent within this paradigm. As a result, 
two smaller subsets of robust molecular markers are produced, 
one corresponding to those genes that are highly expressed 
for most of the patients from the positive group compared 
to the negatives; and the other subset refers to those genes 
that are highly expressed for most of the samples in the nega-
tive group compared to the positives. These subsets of robust 
biomarkers are then validated by training an independent clas-
sifier, such as a Support Vector Machine (SVM), to construct 
highly accurate classifier systems. 
In what genotype and phenotype scenarios have you 
implemented your model and what outcomes have you 
detected?
It is well-known that much more accurate machine-learning 
methods are required to specify and measure phenotypes of 
complex diseases such as cancer. In particular, our focus has 
specifically been to reduce the amount of spurious or false 
positive associations within sophisticated classifier-based 
systems by intelligent feature selection and extraction. More-
over, if it is possible to identify robust biomarkers for cancer 
this will help standardise the definition of the disease to facil-
itate the interpretation and reproducibility of methods and 
results. However, we recognise this is against the challenging 
backdrop of data samples that are of very high dimensionality 
and relatively low sample sizes.
We utilised proteomic and genomic data sets to discover 
the phenotypes that underlie the variations apparent between 
the cancer and control patient groups. Fundamentally, two 
types of outcomes were revealed by our deep mining model, 
both indicating strong likelihoods of a patient having cancer. 
The first outcome indicated a subset of highly positively-
weighted genes whereby the amplifications and gains in the 
gene expression levels were associated with the likelihood 
of a patient having cancer. Conversely, the second outcome 
revealed another subset of genes that were highly negatively-
weighted and coincided with significant downregulation in the 
gene expression levels, and again indicated the strong likeli-
hood of a patient having cancer.
How has your model ameliorated existing models of 
cancer biomarker identification? 
As mentioned earlier, extracting knowledge from omics data-
sets is a serious challenge for machine learning-based solu-
tions due to the ‘curse of dimensionality.’  Whilst some existing 
deep learning (neural network models with many hidden 
layers) approaches appear able to handle ‘curse of dimension-
ality’ issues and improve generalisability, this is typically at the 
expense of long training times, a need for substantial data to 
train the models, and lack of transparency in that it is not able 
to unambiguously state which input features are responsible 
for its behaviour.
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To alleviate the limitations of existing approaches, we intro-
duced SSCAE, a deep feature mining model with an explana-
tory technique that can be used for discovering robust high-
level abstract representations from high dimensional small 
sample size omics datasets and reveal key determinants 
underlying these latent representations. Unlike other systems, 
SSCAE can perform deep classification whilst simultaneously 
revealing the key input features underlying its hidden repre-
sentations. SSCAE’s output decisions were further validated 
using appropriate evaluation metrics and independent model 
validations, thus providing significant confidence as to the 
relevance, robustness, and reproducibility of the discovered 
biomarkers.
How do you think medicine and research could collabo-
rate more efficiently and effectively for better diagnosis 
of cancer?
A significant obstacle for biomarker discovery research 
remains the need for more effective interdisciplinary research 
environments, involving academics, clinicians and govern-
ment working in a co-ordinated and prioritised manner. There 
are relatively few examples of situations where novel omics 
biomarkers originating from the cancer research commu-
nity has found its way into routine clinical practice. Effec-
tive interdisciplinary research is therefore paramount if find-
ings from state-of-the-art machine learning research is to be 
truly exploited and brought into the service of precision medi-
cine e.g. data scientists should have clear routes of access to 
clinicians when evaluating genes identified by their machine 
learning methods. Similarly, clinicians must have fluid access 
to data scientists and bioinformaticians when requiring solu-
tions to real-world problems, such as understanding the 
genetic make-up of new and emerging diseases or pandemics 
e.g., viruses such as COVID-19 and Ebola. 
Based on the outcomes of your research, what do you 
think is the next stage? Is there scope to take your 
research further? 
Moving forward, we will investigate the capacity of SSCAE 
to detect generic biomarkers for selected cancers across a 
range of independent high-quality genomic samples collected 
from different studies. This will further add confidence to the 
significance of the generic biomarkers already discovered by 
SSCAE and indicate which of these the academic and wider 
biomedical community should explore further. Also, with the 
rise of high quality integrated and multi-modal omics data, 
such as the TCGA database which contains a combination of 
genomic, epigenomic, proteomic, imaging and clinical data for 
matched patient groups, will enable us to develop sophisti-
cated ‘integrative models’ that may reveal even more valuable 
indicators of disease. We feel this will provide a sound basis for 
the development of more effective diagnostic and prognostic 
systems in the future.
How do you see your model being used in a real-world 
setting?
SSCAE could be realised as an essential software tool for 
bioinformaticians and clinicians. Bioinformaticians would use 
SSCAE for research and development purposes, evaluating 
various panels of genetic biomarkers for an array of different 
diseases with our deep mining model providing state-of-the-
art analytics to further their research. Clinicians would use 
SSCAE optimised for specific diseases so that they can inter-
rogate the software tool for biomarkers relating to specific 
cancers to establish whether or not patients have cancer 
and if so, to inform specific treatment patterns and proto-
cols (subject to individual patient biomarkers being available to 
SSCAE).
Are there any particular cancers that your approach is 
most suitable for?
Our research provided much support for the strong associ-
ation between gene expression and oestrogen and proges-
terone receptors and the development and treatment of breast 
cancer.  However, our deep mining approach to feature extrac-
tion and selection is generic, and can therefore be applied to 
most, if not all cancers, where an underlying cause is believed 
to have a strong genetic component. 
In our next paper, we will be presenting the outcomes of our 
experiments with our deep mining model for exploring the 
association between mRNA expression data and the positivity 
of both ER and PR receptors in breast cancer. 
Conflict of Interest 
None.  
Extracting knowledge from omics datasets is a serious 
challenge for machine learning-based solutions due to the 
curse of dimensionality
Alzubaidi A, Tepper J, Lotfi A (2020) A Novel Deep Mining Model for Effective Knowledge 
Discovery from Omics Data. Artificial Intelligence in Medicine, 104, 101821.
  REFERENCES
